The NULISA technology by Alamar Corporation integrates a proprietary sequential immunocomplex capture and release workflow with Next-Generation Sequencing (NGS) or qPCR readout to achieve ultra-high sensitivity and scalable multiplexing. This approach enables the detection of low-abundance biomarkers in plasma or biofluid.
By effectively minimizing non-specific background signal, NULISAseq panels deliver attomolar-level sensitivity with high specificity, supporting reliable detection across a wide dynamic range in plasma and other biofluids.
In collaboration with Alamar Biosciences, Biognosys offers NULISAseq assay services tailored for biopharmaceutical and translational research applications. All analyses are conducted in our state-of-the-art facility in Switzerland, utilizing the ARGO HT System for high-throughput and reproducible data generation.
NULISA panels enable deep insights into complex biological processes and protein dynamics. Additionally, the platform supports advanced biomarker discovery with options for GCP-compliant laboratory operations, making it ideal for exploratory profiling of clinical trial samples.
Deepest profiling of inflammatory response.
Quantitate more biomarkers in clinical cohort studies.
Most comprehensive coverage of protein expression in murine models.
Sensitivity meets specificity. One powerful panel for comprehensive neurodegenerative research.
Comprehensive, ultra-sensitive profiling of neurodegenerative disease biology.
Ultra-high sensitivity measurement of your most informative biomarkers.
Detect biomarkers at attomolar concentrations.
Enhanced signal clarity for reliable results.
Analyze numerous targets in a single run.
Optimized for plasma and diverse biofluids.
1. Plasma/Biofluid Sample
2. Load
Load plate with biofluid sample.
3. Run
Sample to pooled library.
4. NGS
Pooled library to NGS.
5. Analyze
Integrated, cloud-based analytics.
Proteomics Service
Delivers comprehensive immune profiling with ultra-high sensitivity, enabling detection of low-abundance cytokines.
Accurate quantification of 250 key inflammation targets in biofluids from a single 25 µL sample, supporting robust biomarker discovery and validation across diverse disease areas.
Its sensitivity facilitates early detection of disease-associated signatures in autoimmune, neuroinflammatory, and immuno-oncology applications.
Proteomics Service
Quantify over 250 proteins and obtain absolute quantities for >150 biomarkers in a single, high-sensitivity assay. With fg/mL sensitivity, the panel enables detection across baseline and disease states. It delivers comprehensive immune coverage and precise quantification for biomarker discovery.
Proteomics Service
Designed for murine translational research, this panel targets 120 key proteins involved in inflammation, neurodegeneration, and oncogenesis.
Leveraging advanced multiplexing, it enables high-sensitivity, high-throughput protein profiling to support investigation of disease mechanisms, biomarker discovery, and evaluation of therapeutic interventions in preclinical models.
Proteomics Service
Enables ultra-sensitive, multiplexed quantification of 120+ neuro-specific and inflammatory proteins in plasma and CSF.
The panel supports detection and monitoring of biomarkers related to amyloid and tau pathology, synaptic function, neurodegeneration, and inflammation. Brain-derived Tau isoforms (pTau217, pTau181, pTau231, tTau) are quantified with high specificity, enabling comprehensive assessment of tau pathology directly from blood.
Proteomics Service
Quantifying 220 biomarkers from just 25 µL of sample, the panel delivers deep coverage of key pathways across Alzheimer’s, Parkinson’s, ALS, MS, TBI, and gliomas. It features extensive tau profiling, including 12 assays for brain-derived and peripheral isoforms, and 25 Parkinson’s-related biomarkers.
With high sensitivity and automated workflows, the panel enables detection of co-pathologies, disease heterogeneity, and early-stage signatures, supporting precision proteomics from discovery to clinical research.
Proteomics Service
Detect important low abundance proteins with attomolar sensitivity (low fg/mL).
Precise measurement of biomarkers is essential for early detection, understanding disease heterogeneity, and predicting therapeutic response in Alzheimer’s disease.
NULISAqPCR Assays provide single- and low-plex solutions for reliable, attomolar-sensitive absolute quantification of low-abundance CNS biomarkers, including key tau isoforms.
Don’t miss out on the latest from Biognosys Group – sign up to receive the latest news, innovations, and expert insights straight to your inbox.
